VALNEVA SE (AYJ.DE) Stock Price, Forecast & Analysis

Europe • Frankfurt Stock Exchange • FRA:AYJ • FR0004056851

3.93 EUR
-0.06 (-1.45%)
Last: Jan 30, 2026, 07:00 PM

AYJ.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap340.76M
Revenue(TTM)274.97M
Net Income(TTM)-120.41M
Shares86.71M
Float76.59M
52 Week High5.31
52 Week Low2.29
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.64
PEN/A
Fwd PEN/A
Earnings (Next)03-18
IPO2007-06-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
AYJ.DE short term performance overview.The bars show the price performance of AYJ.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

AYJ.DE long term performance overview.The bars show the price performance of AYJ.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of AYJ.DE is 3.93 EUR. In the past month the price increased by 0.36%. In the past year, price increased by 42.39%.

VALNEVA SE / AYJ Daily stock chart

AYJ.DE Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to AYJ.DE. When comparing the yearly performance of all stocks, AYJ.DE is one of the better performing stocks in the market, outperforming 83.66% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AYJ.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE. AYJ.DE has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AYJ.DE Financial Highlights

Over the last trailing twelve months AYJ.DE reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -1180% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.86%
ROE -80.02%
Debt/Equity 0.89
Chartmill High Growth Momentum
EPS Q2Q%-271.43%
Sales Q2Q%-35.76%
EPS 1Y (TTM)-1180%
Revenue 1Y (TTM)19.89%

AYJ.DE Forecast & Estimates

11 analysts have analysed AYJ.DE and the average price target is 7.34 EUR. This implies a price increase of 86.69% is expected in the next year compared to the current price of 3.93.

For the next year, analysts expect an EPS growth of -607% and a revenue growth -6.69% for AYJ.DE


Analysts
Analysts81.82
Price Target7.34 (86.77%)
EPS Next Y-607%
Revenue Next Year-6.69%

AYJ.DE Ownership

Ownership
Inst Owners24.02%
Ins Owners0.21%
Short Float %N/A
Short RatioN/A

About AYJ.DE

Company Profile

AYJ logo image Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Company Info

VALNEVA SE

6, Rue Alain Bombard

Saint-Herblain PAYS DE LA LOIRE FR

Employees: 695

AYJ Company Website

AYJ Investor Relations

Phone: 33228073710

VALNEVA SE / AYJ.DE FAQ

What does AYJ do?

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.


What is the stock price of VALNEVA SE today?

The current stock price of AYJ.DE is 3.93 EUR. The price decreased by -1.45% in the last trading session.


Does VALNEVA SE pay dividends?

AYJ.DE does not pay a dividend.


What is the ChartMill rating of VALNEVA SE stock?

AYJ.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the market capitalization of AYJ stock?

VALNEVA SE (AYJ.DE) has a market capitalization of 340.76M EUR. This makes AYJ.DE a Small Cap stock.


What is the ownership structure of VALNEVA SE (AYJ.DE)?

You can find the ownership structure of VALNEVA SE (AYJ.DE) on the Ownership tab.